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Background: The aim of this study was to assess the quality of reporting sample size calculation and underlying design assumptions in pivotal trials of high-risk medical devices
(MDs) for neurological conditions.
Methods: Systematic review of research protocols for publicly registered randomized controlled trials (RCTs). In the absence of a published protocol, principal investigators were
contacted for additional data. To be included, trials had to investigate a high-risk MD, registered between 2005 and 2015, with indications stroke, headache disorders, and epilepsy
as case samples within central nervous system diseases. Extraction of key methodological parameters for sample size calculation was performed independently and peer-reviewed.
Results: In a final sample of seventy-one eligible trials, we collected data from thirty-one trials. Eighteen protocols were obtained from the public domain or principal investigators.
Data availability decreased during the extraction process, with almost all data available for stroke-related trials. Of the thirty-one trials with sample size information available,
twenty-six reported a predefined calculation and underlying assumptions. Justification was given in twenty and evidence for parameter estimation in sixteen trials. Estimates were
most often based on previous research, including RCTs and observational data. Observational data were predominantly represented by retrospective designs. Other references for
parameter estimation indicated a lower level of evidence.
Conclusions: Our systematic review of trials on high-risk MDs confirms previous research, which has documented deficiencies regarding data availability and a lack of reporting on
sample size calculation. More effort is needed to ensure both relevant sources, that is, original research protocols, to be publicly available and reporting requirements to be
standardized.
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The market for high-risk medical devices (MDs) and im-
plants has shown significant growth over the past decade (1).
One of the driving market segments behind this develop-
ment is that of neurostimulation devices. This is due to high
demand for invasive and noninvasive treatment options for
neurological conditions. Demand for such options has been
growing, in part, by increasing incidence and government
funding toward research into such diseases (2). For example,
Storz et al. found that central nervous disease (CNS) disor-
ders are among a group of disease areas with highly active
research (3).
When it comes to decisions regarding the reimbursement
of new procedures involving MDs within a health insurance
system, key players such as regulatory bodies, funding agen-
cies, and patients demand results from clinical trials, such as
randomized controlled trials (RCTs), with high scientific va-
lidity and reliability. It is essential that these stakeholders have
confidence in the research and are aware of the strengths and
weaknesses of the methodologies used for trial implementation
(4). For example, because the effect size strongly influences a
decision, the involved parties should be aware of the relevance
of the sample size that is needed to demonstrate such an effect
according to a prespecified power calculation.The sample size,
in turn, is a decisive part of RCT planning (5). Hence, it is cru-
cial that the reporting of RCTs is transparent with respect to
sample size and, in particular, underlying assumptions regard-
ing the anticipated treatment effect.
Despite its importance, previous studies repeatedly found
a lack of data availability and reporting of the sample size
methodology including justification for the values of a priori
estimates. All of them conclude that sample sizes are poorly
reported, are erroneous, and often based on inaccurate assump-
tions regarding the expected event rate (4;6–9). Nevertheless, a
considerable number of approaches and guidelines for report-
ing in RCTs exists in the literature (10;11). One important ex-
ample is the revised consolidated standards for reporting trials
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(CONSORT) statement, which has been developed to improve
suboptimal reporting of RCTs (4;12).
In addition, leading medical journals (e.g. BMJ, Lancet)
increasingly only publish trials in accordance with the CON-
SORT recommendations and require submitted study publica-
tions to be accompanied by original research protocols (13;14).
Although such guidelines and preconditions clearly specify and
encourage standardized reporting of the sample size methodol-
ogy, deficiencies have still been widely documented in the lit-
erature; even years after these guidelines have first been intro-
duced. Therefore, greater transparency and better justification
of the sample size estimation is recommended to promote the
early detection of shortcomings in study design (4;6;7;15–18).
However, analyses typically focus on pharmaceutical stud-
ies and have been limited for example to specific journals (15,
18), a certain research ethics committee (7;16), a specific study
design (17), or only one study registry (8). To our knowledge,
no such systematic analyses have been performed for trials of
high-risk MDs. Therefore, we formulate two hypotheses re-
garding the documentation of sample size calculation in trials
testing MDs. First, the rationale for underlying assumptions is
incomplete or non-existent in most cases. Second, when sample
size estimation is reported, parameters are derived from scien-
tific evidence of poor quality.
To test these hypotheses, we conducted a systematic review
aiming at assessing the completeness of reporting sample size
calculation and the underlying quality of evidence for sample
size calculation. Complete study protocols are reliable sources
of information with a key role in reducing bias by documenting
a prespecified blueprint with respect to the conduct and analy-
ses of trials (7). We, therefore, primarily focused on the identi-
fication of original research protocols.
METHODS
Trial Search
Our initial search was divided into three steps:
Preliminary search. In the run-up to our systematic examination of
registered trials, we performed an intensive exploratory search
using ClinicalTrials.gov to identify the most frequently investi-
gated indications relying on MDs for neurological conditions.
Based on these results, stroke, epilepsy, and headache disor-
ders, were selected as case samples for further analyses (see
Supplementary Tables 1 and 2). As these three indications
represent a broad spectrum of neurological conditions (e.g.,
chronic versus acute, range of pharmaceutical and nonphar-
maceutical interventions available, high incidence and preva-
lence), they enhance the applicability of our results.
Main search. The second step was a focused search for these three
indications using the two trial resources ClinicalTrials.gov and
the International Clinical Trials Registry Platform (ICTRP) of
the World Health Organization (WHO). We chose these two
clinical trial databases to ensure that the included trials are
as representative as possible. ClinicalTrials.gov represents the
largest and most widely used registry of clinical trials. How-
ever, its focus is on studies conducted in the United States
of America (USA). To mitigate any sample bias, we included
the WHO/ICTRP database, which aggregates trials from many
regional registries around the world, in particular Europe. To
systematically identify all relevant registered clinical trials for
MDs aimed at the selected indications, search criteria such as
the indication, the type of study and the trial phase were ap-
plied. Only trials registered between 2005 and 2015 were in-
cluded, as legal and regulatory frameworks have not changed
significantly in this period. The detailed search strategy of both
databases is provided as supplementary material of this article
(see Supplementary Table 3).
Identification of full study protocols. The third step was to identify study
protocols including extra material such as statistical appendices
for the previously identified trials. In case no study protocol
was available, we searched for the corresponding study article.
Additionally, and as a last resort, we attempted to contact the
principal investigators or trial sponsors to ask for provision of
the missing protocol or additional data such as the statistical
analysis plan.
Trial Selection
Inclusion and exclusion criteria were determined a priori to
guide trial screening and selection to ensure identification of
the most relevant body of literature with respect to the research
question. Specifically, we included all interventional, random-
ized, comparative phase II, III, and IV trials of MDs defined ac-
cording to the EU Directives 90/385/EEC on active implantable
MDs and 93/42/EEC on MDs with a risk class of at least
IIB (19).
We excluded trials with study designs other than RCTs, tri-
als that investigated other healthcare interventions (e.g., phar-
maceuticals), trials that focused on MDs of risk classes below
IIB, and/or trials that did not match the preset indications. A
tabular presentation of all inclusion and exclusion criteria used
for data selection is given in the Supplementary Table 4.
Database Generation and Data Extraction
General characteristics of the trials from the databases were
extracted into a spreadsheet, including, for example, disease
area, study design, type, and the risk class of the MD. For each
trial, the protocol (including statistical appendices, amend-
ments, etc.) and in the absence of a protocol the corresponding
publication or any additional information from the principal
investigators or sponsors was reviewed. We then extracted data
with respect to key methodological items relevant for assessing
the sample size calculation. These methodological extraction
items were defined based on the literature and discussions
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 33:1, 2017 104
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462317000265
Downloaded from https://www.cambridge.org/core. TU Berlin Universitaetsbibliothek, on 11 Feb 2019 at 17:38:11, subject to the Cambridge Core terms of use, available at
Sample size estimation in medical device trials
among the research team. The extraction followed a hierar-
chical order. We started with the availability of sample size
calculations, followed by design assumptions, their justifica-
tion, and finally the underlying scientific evidence. Any of the
subsequent items were only relevant, if the preceding items
were answered positively. We did not assess the appropriateness
of the methods used for sample size estimation. The definitions
of the extraction items used are as follows:
1. Reporting Sample Size Calculation. This item is a binary “yes/no” option
and refers to the reporting in the document only.
2. Reporting Design Assumptions. This item is a binary “yes/no” option and
refers to the reporting in the document only. The term “design assump-
tions” relates to the main elements used for calculation of the sample size
guided by the CONSORT recommendations (20). These include: (i) the
estimated outcomes in each group, which suggests the clinically impor-
tant target difference between the intervention groups; (ii) the α (type I)
error level; (iii) the statistical power (or the ß (type II) error level); and
(iv) for continuous outcomes, the standard deviation of the measurements.
To be assessed as “reported” it was presumed that these elements were
presented.
3. Reporting Justification. This item is a binary “yes/no” option and refers
to the reporting in the document only. Justification required an expla-
nation for the selection of the value(s) for the sample size calculation
including a discussion why these were assessed as reasonable for the
study.
4. Reporting Evidence on which Assumptions Are Based. For this item, mul-
tiple sources were possible including:
results from a previous/preliminary trial (RCT, observational data, etc.),
results from a review (systematic or narrative),
other (interim analyses, databases, expert opinions, etc.).
All extractions were carried out by one researcher and in-
dependently checked by another. Discrepancies were discussed
and a final data pool was consented. The detailed data sheets
for all three indications will be provided on request.
RESULTS
Study Pool
Our search yielded a total of 1,074 publicly registered trials,
with 616 remaining after removal of duplicates. Subsequent
screening for relevance, using our predefined in- and exclusion
criteria (see Supplementary Table 4), resulted in the exclusion
of further 543 trials. Seventy-three trials (forty-nine on stroke
and twelve studies each on headache disorders and epilepsy,
respectively) fulfilled the inclusion criteria and were included
in our sample (see Figure 1).
Data Pool for Qualitative Synthesis
Documents Obtained from Registry Databases. Overall, for twelve of the
seventy-three trials, full study protocols were available in the
registry databases. These protocols were exlusively from the
stroke sub-sample. For sixty-one trials (thirty-seven for stroke
and twelve for each headache disorders and epilepsy, respec-
tively), no full study protocols could be obtained (see Figure 2).
For nine of the sixty-one trials, a corresponding publica-
tion describing the study methods was identified in the reg-
istry databases (five for stroke, two for epilepsy, and two for
headache disorders) (see Figure 2).
Information Gathered from Experts. Regarding the sixty-one trials with
no publicly available study protocol in the registry databases,
we contacted a total of seventy-six principal investigators
and/or sponsors to obtain additional information on fifty-seven
studies. For four studies, no current contact information was
available.
Attempts to contact these experts were unsuccessful for
more than half of the studies (34 studies). However, of the
twenty-three responses received, all regarding different studies,
fourteen were judged as useful and nine were negative (i.e., re-
fusal to share information, mainly because of confidentiality
or time constraints). Of the useful responses, six yielded addi-
tional full study protocols (five for stroke and one for epilepsy)
(see Figure 2). The other eight contained additional informa-
tion from principal investigators and/or sponsors themselves,
such as protocol extracts or descriptions regarding the sample
size estimation. Based on this additional information, two trials
were subsequently excluded, due to the respondents’ disclosure
about the exact study design (e.g., a feasibility study with no
planned sample size calculation did not match our inclusion
criteria) (see Figure 2). No additional supplementary publica-
tions were provided.
Final Data Pool. Overall, a total of seventy-one trials fullfilled our
inclusion criteria. From these trials, we deduced our final data
pool for qualitative analyses, consisting of thirty-one trials for
which sufficient data regarding the sample size estimation were
available. Specifically, in eighteen cases corresponding full re-
search protocols could be obtained. For another eight, we relied
on publications. Finally, for five studies, experts provided suf-
ficient additional information to justify consideration in subse-
quent analyses. Note that, despite an initial number of nine pub-
lications, one publication was disregarded in favor of a study
protocol provided by an expert upon request. Moreover, for one
trial we did obtain additional information from an expert, but
could not consider it in subsequent analyses due to lack of de-
tail (see Figure 2).
Overall Data Availability
Data availability decreased along the hierarchical data extrac-
tion process (see Figure 3). As documented above, less than
half of the included trials (31 of 71), provided any data for fur-
ther analysis (i.e., study protocol, publication, or additional data
provided by means of experts). Eighty percent of the available
data stemmed from stroke trials (twenty-five trials). Data acces-
sibility decreased further along the process, as only half of these
trials (sixteen of thirty-one) reported any scientific evidence on
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Figure 1. Trial selection.
the assumptions they were based on. At this point, data only
came from stroke related trials. No data were available for the
indications epilepsy and headache disorders.
Reporting of Sample Size Methodology
Among the thirty-one trials for which data were available,
twenty-six reported an a priori sample size calculation. Five tri-
als did not provide any information. All of the twenty-six trials
containing information about sample size estimation also stated
underlying assumptions. Of the trials that reported assump-
tions, twenty justified the respective assumptions, whereas six
trials did not. Within the twenty trials that provided a justifica-
tion, sixteen reported evidence from which values a priori esti-
mates were derived. The remaining four trials did not provide
any reasoning supported by data.
Evidence behind the justifications was only available for
stroke trials. A single trial could refer to multiple study types
and studies. For example, a trial could refer to four observa-
tional studies, of which one was retrospective and three were
prospective. Our results were as follows: where justified, pa-
rameters were most often set based on previous/preliminary re-
search (in fourteen of sixteen trials), coming from RCTs (in
six trials), single-arm studies (in two trials) and observational
data (in six trials). The observational data used by the six tri-
als stemmed from five retrospective and three prospective stud-
ies. In three trials, the study design used for estimation was
not assessable due to a lack of detailed information. More-
over, in three of sixteen trials, approximations were also based
on reviews. Two reviews were nonsystematic or narrative ar-
ticles; one review was conducted systematically. Nevertheless,
the studies included in the systematic review were predomi-
nately retrospective. Finally, in three trials, variables were de-
duced from results of another type of evidence such as an in-
terim or a database analysis. Details of sample size reporting
are given in Figure 4.
DISCUSSION
Our results are in line with previous research documenting poor
reporting and, for the first time, highlight deficiencies within
trials testing high-risk MDs.
In this systematic review of seventy-one trials from the past
10 years in the area of CNS diseases, findings are twofold. On
the one hand, the review primarily shows the generally poor
data availability. On the other hand, it illustrates the opacity of
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Figure 2. Data pool for qualitative analysis.
sample size methodology, especially when it comes to scientific
evidence supporting parameter estimation. More precisely, for
fewer than half of the included trials we were able to find data
for our analysis. Almost all information remaining after our ex-
traction process stemmed from stroke trials, which shows the
need for more research on other indications in which high-risk
MDs are involved.
Although additional data obtained from experts or a corre-
sponding paper added some information that we used to fill any
gaps, we recognized that protocols are the most valuable source
for information on study designs. However, of the trials for
which data were available, only half reported evidence under-
lying parameter estimation. The remaining trials did not report
any evidence or lacked detail, making any assessment impossi-
ble. When parameter estimates were justified based on clinical
evidence these came most often from previous trials includ-
ing RCTs. However, at least a comparable number of the tri-
als extrapolated their sample size parameter from observational
data, which represented predominantly retrospective study
designs.
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Figure 3. Data availability.
Figure 4. Sample size reporting (multiple sources possible).
Other data used for parameter estimation were all of
lower level of evidence, including single-arm studies, narrative
reviews, and results from interim analyses. This finding is
particularly important given the large influence that parameter
estimation has on sample size calculation and consequently
on the reliability of the study outcomes. For example, the
recent study by Castonguay et al. reviewed the accuracy with
which the median progression-free survival (PFS) and overall
survival (OS) in the control arm had been estimated in studies
of epithelial ovarian cancer between 2000 and 2010 (21). Their
results highlight that PFS and OS of the control arm have
frequently been underestimated, which means that the initial
statistical assumptions of these trials may have been inaccurate.
In those studies in which significant underestimation arose,
the authors noted the negative impact on the power to detect
absolute differences in the respective endpoints. This decrease
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in power consequently compromises the ultimate results of a
trial, even before it has started.
Considering that our sample focused on trials regarding
high-risk MDs, specifically from a patient safety perspective,
the limited transparency documented in this systematic review
is alarming. Very recently, Rathi et al. aimed to characterize
the clinical evidence generated for high-risk therapeutic de-
vices initially approved by means of the US Food and Drug Ad-
ministration (FDA) Premarket Approval (PMA) pathway. Their
results support our findings by showing that the amount and
quality of evidence generated over the total product life cycle
of MDs varies widely. Most devices have been, or will be, eval-
uated by only a few studies, which often focus on surrogate
markers in small numbers of patients followed up over short
periods of time and study indications that differ from the origi-
nal FDA-approved indication (22).
By now, the issue of inadequate or missing evidence has
found its way into public discourse, as stakeholders have iden-
tified it as an obstacle for new technologies trying to enter the
market. More precisely, it is postulated that healthcare deci-
sion makers choose not to introduce innovative treatment op-
tions in such situations and instead wait until stronger evidence
has been generated; for example, by implementing the coverage
with evidence development approach (23). One project aiming
at mitigating this evidence gap is the core protocol pilot within
the EUnetHTA network, which attempts to develop and test a
common methodological basis for additional evidence genera-
tion on a European level (24).
Strengths and Limitations
The main strength of this study is the comprehensive and
systematic approach to the identification of RCTs in two trial
registries in the area of CNS diseases. To our knowledge, this is
the first review regarding reporting quality in studies of MDs,
primarily based on original research protocols. However, we
acknowledge several limitations.
We chose to focus our search on trial registries to minimize
publication bias. However, because trial registration is still not
obligatory in Europe, there is a potential risk that our search did
not capture some relevant studies.
Our analysis is mainly based on stroke trials, as only scarce
data were available for the indications headache disorders and
epilepsy. This consequently restricts generalizability of our
findings in the area of CNS diseases.
Another limitation is that for four trials, contact informa-
tion was not available or erroneous, which highlights the need
for updating email addresses of responsible parties in the reg-
istries. In addition, as the items of the registries do not capture
this information, we had to make this assessment ourselves. To
ensure a structured and understandable approach of assessment,
we used the MD guidance manual published by the European
Commission (EC) (19).
Although a duplicate data check was performed aiming at
reducing bias, the assessment of the risk classification may still
contain errors. However, we believe that our results are valid
because we focused on high-risk MDs in general and errors
might have occurred only within the high-risk classes IIB and
III. Lastly, we did not assess whether the trials in our sample
were properly powered or whether the assumptions made were
appropriate.
Implications for Policy
Our findings have relevant implications for policy. First, our
results show the importance of an improvement in data avail-
ability. We recommend that journals enforce inclusion of pro-
tocols for all submissions to enable public access to original
research data. Although several journals have already made
protocol submission with a manuscript as a condition, there
is much room for improvement. Furthermore, even if guide-
lines on reporting exist, more efforts are needed to ensure high
quality reporting. Therefore, we suggest tightening submission
requirements of publications by a stricter compliance to CON-
SORT recommendations.
In addition, as ethics commitees and regulatory authorities
such as the German Federal Institute for Drugs and Medical
Devices receive the results prior to scientific review, they have
an important gate-keeping role in ensuring that submitted trials
are adequately powered and well documented. Moreover, when
advising study investigators, they should also address statisti-
cal elements such as the realistic calculation of sample size.
Given the importance of trial protocols, guidelines for writing
study reports that help to facilitate complete documentation of
key trial elements, such as SPIRIT, should be routinely used
(25). In addition, current initiatives such as the EUnetHTA pilot
core project help to give clear guidance on complete transparent
and standardized reporting of key methodological parameters
in RCTs.
CONCLUSION
Our research confirms previous findings documenting a lack
of public access to original data and poor reporting of sample
size calculation, especially with respect to underlying evidence
supporting study design assumptions. Consequences might be
misinterpretations of study results and the inability to make
proper decisions in healthcare. Transparent reporting of sam-
ple size calculation including justification of underlying as-
sumptions is important from a scientific as well as an ethical
point of view to indicate the quality of how a trial has been
conducted. Journal editors, ethics commitees, and regulatory
authorities play a key role in facilitiating improved data avail-
ability, as well as correct, transparent, and standardized report-
ing. These factors are necessary to enable critical evaluation of
RCTs.
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